Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 6/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HK1 | P19367 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149718 | 0.85 | NOS1 (0.51) | RAB9ANPC1MAPTSMN1; SMN2NOS1 | |
| SCHEMBL623682 | 0.82 | NPC1 (0.59) | RAB9ANPC1MAPTNOS1LTA4H | |
| SCHEMBL30513256 | 0.82 | RAB9A (0.58) | RAB9ANPC1MAPTSMN1; SMN2NOS1 | |
| SCHEMBL1915556 | 0.81 | NOS1 (0.71) | RAB9ANPC1MAPTSMN1; SMN2NOS1 | |
| SCHEMBL27603499 | 0.80 | NOS1 (0.50) | RAB9ANPC1MAPTSMN1; SMN2NOS1 | |
| SCHEMBL1136768 | 0.79 | CYP17A1 (0.51) | RAB9ANPC1MAPTSMN1; SMN2NOS1 | |
| SCHEMBL13148615 | 0.79 | KMT2A (0.59) | MAPTSMN1; SMN2EPHX2 | |
| SCHEMBL1136660 | 0.78 | LTA4H (0.68) | RAB9ANPC1MAPTSMN1; SMN2LTA4H | |
| SCHEMBL28306246 | 0.78 | NOS1 (0.45) | RAB9ANPC1MAPTSMN1; SMN2NOS1 | |
| SCHEMBL14489267 | 0.77 | NOS1 (0.44) | RAB9ANPC1MAPTSMN1; SMN2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625921-B2 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625921-B2 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7569689-B2 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569689-B2 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-04 | — | — | US | disclosed |
| US-7326728-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326728-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1708699-A4 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF- K .B ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1708699-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF- K .B ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050182110-A1 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-18 | — | — | US | disclosed |
| WO-2005072729-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182110-A1 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof | NR3C1, NFRKB, NCOR1 | RAB9A 2116/4885NPC1 614/4885MAPT 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.